Medicine and Dentistry
Ulcerative Colitis
100%
Patient with Inflammatory Bowel Disease
50%
Inflammatory Bowel Disease
48%
Patient with Ulcerative Colitis
43%
Crohn's Disease
35%
Stenosis
33%
Patient with Crohn's Disease
29%
Disease Course
29%
Incision
28%
Biological Product
23%
Disease Activity
21%
Elderly Patient
20%
Infliximab
20%
Diagnosis
18%
Primary Sclerosing Cholangitis
18%
Lower Digestive Tract
18%
Adenoma
18%
Multivariate Analysis
18%
Biological Marker
17%
Organoid
17%
Small Intestine
17%
Malignant Neoplasm
16%
Stent Placement
14%
Prospective Study
13%
Propensity Score Matching
13%
Colorectal Carcinoma
12%
Endoscopy
12%
Carcinogenesis
12%
Tumor Necrosis Factor
12%
Stricture
12%
Diarrhea
11%
Mesalazine
11%
Colectomy
11%
Colonoscopy
10%
Colorectal Adenoma
10%
Colorectal Tumor
10%
Immunosuppressive Treatment
10%
Self-Expandable Metallic Stent
10%
Therapeutic Agent
10%
Tacrolimus
10%
Bleeding
10%
Drug Delivery System
9%
Odds Ratio
9%
Neoplasm
9%
Disease Predisposition
9%
Acute Pancreatitis
9%
Total Parenteral Nutrition
9%
Liquid Biopsy
9%
Predictive Factor
9%
Retrospective Study
9%
Pharmacology, Toxicology and Pharmaceutical Science
Ulcerative Colitis
62%
Crohn's Disease
60%
Inflammatory Bowel Disease
56%
Remission
23%
Mercaptopurine
22%
Ustekinumab
20%
Aminosalicylic Acid
17%
Biological Product
15%
Diseases
13%
Combination Therapy
13%
Disease Activity
12%
Disease Course
10%
Disease Predisposition
9%
Diarrhea
9%
Primary Sclerosing Cholangitis
9%
Alpha2 Glycoprotein
9%
Chromosome Mosaicism
9%
Retrospective Study
9%
Leucine
9%
Coronavirinae
9%
Congenital Malformation
9%
Necrosis
9%
Diffuse Large B Cell Lymphoma
9%
Arginine
9%
Generic Drug
9%
Budesonide
9%
Biosimilar Agent
9%
Randomized Controlled Trial
9%
Infliximab
8%
Drug Delivery System
8%
Tumor Necrosis Factor Inhibitor
7%
Prednisolone
7%
Adverse Event
7%
ICD-10
5%
Adalimumab
5%
Immunology and Microbiology
Inflammatory Bowel Disease
72%
Ulcerative Colitis
50%
Crohn's Disease
48%
Infliximab
24%
Pharmacogenomics
18%
Organoid
17%
Ustekinumab
11%
Vedolizumab
11%
Antibody Titer
10%
Immunosuppressive Therapy
9%
Genotype
9%
Seropositivity
9%
Tacrolimus
9%
Immunosuppressive Drug
9%
Intravenous Immunoglobulin
9%
Chromosome Mosaicism
9%
HLA DQA1 Antigen
9%
B Cell
9%
Allogeneic Hematopoietic Stem Cell Transplantation
9%
COVID-19
9%
TNF Inhibitor
9%
Acute Pancreatitis
9%
Primary Sclerosing Cholangitis
9%
Fibroblast
9%
Biological Product
9%
Prednisolone
7%
Codon
7%
Titer
6%
Normal Human
6%
Tofacitinib
5%